significantNew research
Swedish and Danish population-based studies reveal higher SM prevalence than expected
Systemic Mastocytosis →Summary
Two large Scandinavian population-based studies found SM prevalence of 11-24 per 100,000 — considerably higher than previously thought. Increasing incidence attributed to improved diagnostics and disease awareness rather than true increase in disease occurrence.
Source
Grade Bcohort
Epidemiology of mastocytosis: a population-based study (Sweden)
Ungerstedt J, Ljung C, Engstrom-Laurent A · Acta Oncologica · 2024
- •Prevalence 23.9 per 100,000 in Sweden
- •Annual incidence 1.56 per 100,000
- •Increasing incidence attributed to improved diagnostics
More from Systemic Mastocytosis
significantTreatment update
PIONEER 3-year follow-up confirms sustained avapritinib benefit in ISM
breakthroughTreatment update
Avapritinib FDA-approved for indolent systemic mastocytosis (PIONEER trial)
incrementalTreatment update
Avapritinib molecular responses in advanced SM: 30% achieve D816V undetectable
significantGenetic finding
WHO 2022 and ICC 2022 classification updates published
ID: systemic-mastocytosis-update-3Type: new_researchImpact: significant